Literature DB >> 22051443

Treatment of complex ischial pressure sores with free partial lateral latissimus dorsi musculocutaneous flaps in paraplegic patients.

Jinguang He1, Hua Xu, Tao Wang, Sunxiang Ma, Jiasheng Dong.   

Abstract

In paraplegic patients dependent on their upper body for mobility, the latissimus dorsi muscle is generally unacceptable for microsurgical reconstruction of complex ischial defect. To avoid total muscle function loss, a portion of the lateral latissimus dorsi musculocutaneous flap can instead be harvested. From February 1999 to March 2009, 11 paraplegic patients with complex ischial pressure sores were prospectively recruited. The reconstruction was performed using a free partial lateral latissimus dorsi musculocutaneous flap. The follow-up period ranged from 18 to 114 months (mean, 60 months). All flaps survived postoperatively. No recurrence occurred in our series. All patients experienced various degrees of back tightness, shoulder weakness and limited shoulder motion since surgery, which were relieved within 9 months. The free partial lateral latissimus dorsi musculocutaneous flap can be a good alternative for covering severe infected ischial defect. Shoulder functional deficits will lessen over time and normal function will be regained gradually.
Copyright © 2011 British Association of Plastic, Reconstructive and Aesthetic Surgeons. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22051443     DOI: 10.1016/j.bjps.2011.10.001

Source DB:  PubMed          Journal:  J Plast Reconstr Aesthet Surg        ISSN: 1748-6815            Impact factor:   2.740


  2 in total

1.  The combination application of space filling and closed irrigation suction in reconstruction of sacral decubitus ulcer.

Authors:  Liang Weizhong; Zhao Zuojun; Wu Junling; Ai Hongmei
Journal:  Int Surg       Date:  2014 Sep-Oct

2.  Occipital pressure sores in two neonates.

Authors:  Yi Liu; Bin Xiao; Cheng Zhang; Zhihong Su
Journal:  Burns Trauma       Date:  2015-11-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.